

## Citalopram (Celexa®)

Citalopram (Celexa®) belongs to a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs). It is primarily used to treat depression.

Jamie, based on your genetic result, your body is likely to have a typical response to citalopram (Celexa®).

This means that based on the [DNA variants](#) we tested, citalopram (Celexa®) is likely to work as expected for you. However, other factors – such as having a DNA variant not included in this test, certain health conditions, or taking other medications – may influence your response. **Do not use this result to start, stop, or change any course of treatment.** Medications should always be taken as directed.

### Likely typical response

to citalopram (Celexa®)

→ [Learn more about your result](#)

### Keep in mind



If you are already taking this medication, **continue your treatment as directed** unless your doctor recommends a change.



**Other factors** besides your genetics can also affect your body's response to this medication.



This test **does not include all possible DNA variants** that may affect your body's response to this medication.



This result **does not apply to** all antidepressants, including fluoxetine and paroxetine.

### About citalopram

Also known as: Celexa® (Celexa® is a registered trademark of Forest Laboratories, Inc.)



#### Primary uses of this medication

Citalopram is used to treat depression. It belongs to a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs).



#### How this medication works

Serotonin is a chemical messenger that carries signals between brain cells. SSRI antidepressants help treat depression by increasing levels of serotonin in the brain.

Read more at: [MedlinePlus](#)<sup>™</sup> [Mayo Clinic](#)<sup>™</sup>

Share a summary of your Pharmacogenetics reports with a healthcare professional.

If you ever need treatment with citalopram, a healthcare professional like your doctor or pharmacist may be able to use this report for reference.

**Do not use this report to start, stop, or change any course of treatment.** Medications should always be taken as directed.



Print summary

### Your Genetic Result

#### CYP2C19 Drug Metabolism

Predicted intermediate metabolizer



[View report >](#)

### References

- Cooke MJ et al. (2013). "Citalopram and cardiac toxicity." *Eur J Clin Pharmacol.* 69(4):755-60. <sup>1</sup>
- de Vos A et al. (2011). "Association Between CYP2C19\*17 and Metabolism of Amitriptyline, Citalopram and Clomipramine in Dutch Hospitalized Patients." *Pharmacogenomics J.* 11(5):359-67. <sup>2</sup>
- Herrlin K et al. (2003). "Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes." *Br J Clin Pharmacol.* 56(4):415-21. <sup>3</sup>
- Hicks JK et al. (2015). "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors." *Clin Pharmacol Ther.* 98(2):127-34. <sup>4</sup>
- Kumar Y et al. (2014). "CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation." *J Psychopharmacol.* 28(12):1143-8. <sup>5</sup>
- U.S. Food and Drug Administration. "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses." Retrieved November 1, 2019, from <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related> <sup>6</sup>
- U.S. Food and Drug Administration (2020). "Table of Pharmacogenetic Associations." Retrieved December 21, 2020 from <https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations> <sup>7</sup>
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research. "Celexa® (citalopram hydrobromide) NDA 020822 label." Retrieved October 20, 2019 from [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/1998/20822b1.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20822b1.pdf) <sup>8</sup>
- Yu BN et al. (2003). "Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19." *Drug Metab Dispos.* 31(10):1255-9. <sup>9</sup>

### Change Log

Your report may occasionally be updated based on new information. This Change Log describes updates and revisions to this report.

Date	Change
May 19, 2021	Citalopram (Celexa®) report created.



Give the gift of DNA discovery.

Gift a kit

Refer friends, earn rewards.

Get reward

#### ANCESTRY

[Ancestry Overview](#)  
[All Ancestry Reports](#)  
[Ancestry Composition](#)  
[DNA Relatives](#)  
[Order Your DNA Book](#)

#### HEALTH & TRAITS

[Health & Traits Overview](#)  
[All Health & Traits Reports](#)  
[My Health Action Plan](#)  
[Health Predisposition](#)  
[Pharmacogenetics](#)  
[Carrier Status](#)  
[Wellness](#)  
[Traits](#)

#### RESEARCH

[Research Overview](#)  
[Surveys and Studies](#)  
[Edit Answers](#)  
[Publications](#)

#### FAMILY & FRIENDS

[View all DNA Relatives](#)  
[Family Tree](#)  
[Your Connections](#)  
[GrandTree](#)  
[Advanced DNA Comparison](#)